Intra-Abdominal Infections Clinical Trial
Official title:
Abdominal SepsiS Study: Epidemiology of Etiology and Outcome
The aim of the project is to perform a multinational, prospective, observational study on IAIs (IntraAbdominal Infections) in critically ill patients; special emphasis will be given to epidemiology and outcomes.
To investigate microbiology and/or drug resistance patterns related to: Geographical region,
Source of IAI, Upper GI tract perforation (stomach & duodenum), Lower GI tract perforation
(jejunum, ileum, colon, rectum), Primary peritonitis, Peritoneal dialysis-related
peritonitis, Intra-abdominal abscess, Pancreatic infection, Biliary tract infection,
Typhlitis, Toxic megacolon.
To check the Origin of IAI: community-acquired, early-onset healthcare-associated,
late-onset healthcare-associated.
To describe physician's antimicrobial prescription patterns related to a classification grid
that stratifies IAIs according to disease expression, community or healthcare origin, and
anatomical disruption.
To investigate outcomes (clinical response, need for surgical revision, length of
hospitalization, and mortality) related to: Classification of IAI, Severity of acute illness
at time of diagnosis (SOFA score) and clinical response after 48-72 hrs. (SOFA score),
Processes of care (Time to 1st antimicrobial dose, Time to source control, Type of source
control intervention (laparotomy, percutaneous drainage, high volume peritoneal lavage,
restoration of anatomy and function), Need for (unplanned) surgical revision (uncontrolled
infection source), Frequency of microbiological sampling and delay of results)), Pathogens
involved and empirical antimicrobial coverage; special emphasis will be given, to coverage
of multidrug resistant Enterobacteriaceae, Pseudomonas aeruginosa, enterococci and Candida
species, Duration of antimicrobial therapy, Underlying conditions
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT04240288 -
Procalcitonin Guided Antibiotic Therapy
|
N/A | |
| Completed |
NCT01473836 -
A Phase 3 Study Of Intravenous Metronidazole For Intrabdominal Infection
|
Phase 3 | |
| Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
| Terminated |
NCT03354754 -
LYS228 PK, Clinical Response, Safety and Tolerability in Patients With Complicated Intra-abdominal Infection (cIAI)
|
Phase 2 | |
| Completed |
NCT00965848 -
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
|
Phase 4 | |
| Completed |
NCT01506271 -
Study of the Safety, Tolerability, and Efficacy of Relebactam (MK-7655) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone to Treat Complicated Intra-Abdominal Infection [cIAI] (MK-7655-004)
|
Phase 2 | |
| Completed |
NCT05628493 -
Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction
|
||
| Recruiting |
NCT04094818 -
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections and Suspected Sepsis
|
||
| Withdrawn |
NCT05639504 -
Sepsis Prognosis and Diagnosis in the Emergency Department (SPEED)
|
||
| Completed |
NCT00827541 -
Post-Authorization Study Evaluating Safety Of Tigecycline
|
N/A | |
| Completed |
NCT01789905 -
Tygacil Drug Use Investigation
|